The early stages of biologic drug development are critical to long-term clinical and commercial success. As biologics become more complex, an integrated approach to candidate selection, preclinical evaluation, and manufacturing readiness is essential.
This on-demand webinar explores how early use of advanced technologies—such as in silico tools for immunosafety, immunogenicity, and manufacturability prediction—combined with scalable platforms like the GS Gene Expression System®, can improve candidate selection, streamline progression to cell line development, and reduce downstream risks.
We also highlight common development pitfalls and share actionable strategies to accelerate the transition from late discovery to first-in-human studies.
Watch if you would like to:
- Understand how in silico tools can reduce development risks and support IND submissions.
- Learn how early adoption of scalable expression systems can optimize development and manufacturing.
- Gain strategies to avoid common pitfalls and speed up clinical readiness.